… , while the previous biologics omalizumab targets against … on the current biologics, as well
as highlights the limitations, … drivers of this inflammation is IL-5, an inflammatory cytokine …

… proinflammatory cytokines, the LEAPS therapeutic vaccines specifically modulate the ongoing
antigen-specific, disease-driving, proinflammatory … therapy targeting several cytokines, as …

… and IL-1β are prototypic proinflammatory cytokines that act by … downstream signals culminating
in inflammatory processes. IL… Nevertheless, our systematic review has several limitations. …

… To limit the scope of this review, we focus on recombinant … IL-10-mediated inhibition
proinflammatory cytokine production by … improved biologic manufacturability. More recently, …

… Biologic-based targeted anti-inflammatory approaches in patients with COVID-19. RA, …
limit the ability to achieve sustained drug delivery and therapeutic benefits. On the other hand, …

… Cytokine blockers Biologic agents targeting cytokines were developed based on the
recognition of the pivotal role of proinflammatory cytokines in the pathogenesis of rheumatic …

… biologics that target cytokines such as GM-CSF and IL-20 have failed to show superiority
over TNF-targeting … However, the burden of medical expenses and problems of medical eco…

… airway inflammation and remodelling, which are responsible for variable airflow limitation
and … Other experimental biologics target upstream innate cytokines such as thymic stromal …

… other molecules, distinct from the currently approved biologics and targeted synthetic …
inflammatory cytokines in PsA pathogenesis and clinical implications of targeting these cytokines …

… We also summarize the clinical trials for gene therapy targeting inflammatory cytokines for
… Such disadvantages elicit the quick development of nonviral vectors such as hydrogels and …